Press release
Polycythemia Market Accelerated by Breakthrough PV Therapies and Pipeline Momentum | Novartis AG, Incyte Corporation, Bristol-Myers Squibb Company
Polycythemia Market
Polycythemia Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With rising interest in targeted JAK2 therapies, improved diagnostic workflows, and expanding supportive care options, the report delivers strategic insights to support stakeholders from 2025 to 2033.
Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/polycythemia-market?ophp
In 2025, therapeutic R&D accelerated for polycythemia vera: rusfertide demonstrated significant reduction in therapeutic phlebotomy needs in clinical studies, and the FDA granted fast-track designation to givinostat - both developments sharpening the pipeline and potentially shifting treatment paradigms.
Polycythemia Market Competitors Overview:
Novartis AG, Incyte Corporation, Bristol-Myers Squibb Company, PharmaEssentia Corporation, TAJ LIFE SCIENCES PVT. LTD, Genetec Lifesciences, Teva Pharmaceuticals, Medyra Pharmaceuticals, Viatris, Apotex Inc and among others.
Important Industry Updates:
In September 2024, PharmaEssentia Corporation, a Taiwan-based biopharmaceutical innovator, has signed an exclusive licensing agreement with FORUS Therapeutics Inc for the registration and distribution of BESREMi (ropeginterferon alfa-2b-njft) for the treatment of polycythemia vera (PV) in Canada, leveraging its expertise in hematology and oncology.
In January 2024, a new treatment for polycythemia vera, a potentially fatal blood cancer, has shown potential in controlling overproduction of red blood cells. The drug rusfertide, developed by the Icahn School of Medicine at Mount Sinai, limited excess red blood cell production over 28 weeks, suggesting it could potentially replace traditional phlebotomy, a common treatment that has been a burden for many patients.
Methodology and Scope
The Polycythemia Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/polycythemia-market?ophp
Polycythemia Market Segments Overview:
By Type (Primary polycythemia, Secondary polycythemia, Pseudopolycythemia)
By Drug Class (Antimetabolites, JAK2 inhibitors, Myelosuppressive Agents, Selective Serotonin Reuptake Inhibitors, Folic acid, Others)
By Route of Administration (Oral, Intravenous, Intramuscular)
By End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Regional Overview for Polycythemia Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=polycythemia-market
The Report Covers:
➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.
People Also Ask:
➤ What are the current global trends in sales, production, imports, and exports within the Polycythemia market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Polycythemia market?
Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycythemia Market Accelerated by Breakthrough PV Therapies and Pipeline Momentum | Novartis AG, Incyte Corporation, Bristol-Myers Squibb Company here
News-ID: 4142647 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Plant Antifreeze Market 2031 | Growth Drivers, Trends & Market For …
Market Size and Growth
Global Plant Antifreeze Market reached US$ 1.9 billion in 2022 and is expected to reach US$ 2.9 billion by 2030, growing with a CAGR of 5.2% during the forecast period 2023-2030.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/plant-antifreeze-market?sb
Key Development:
United States: Recent Developments
✅ In December 2025, a new review summarized advances in transcriptional regulation of cold stress tolerance highlighting how…
United States Hypertriglyceridemia Treatment Market 2031 | Growth Drivers, Key P …
Market Size and Growth
Global Hypertriglyceridemia Treatment Market is expected to reach at a high CAGR during the forecast period 2023-2030.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/hypertriglyceridemia-treatment-market?sb
Key Development:
United States: Recent Hypertriglyceridemia Treatment Developments
✅ In December 2025, the U.S. FDA granted Breakthrough Therapy designation to plozasiran as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (SHTG), expediting development…
United States Generative AI Market to Reach USD 1,022.41 Billion by 2032 | Stron …
Generative AI Market Overview
The Global Generative AI Market reached USD 45.56 billion in 2024 and is projected to grow exponentially, reaching USD 1,022.41 billion by 2032, expanding at an impressive CAGR of 47.53% during 2025-2032. The market's remarkable growth is driven by the rapid adoption of generative AI technologies across industries such as entertainment, healthcare, marketing, design, and manufacturing. Organizations are increasingly recognizing the potential of generative AI to revolutionize…
United States Artificial Intelligence in Healthcare Market to Reach USD 187.7 Bi …
Artificial Intelligence in Healthcare Market Overview
The Global Artificial Intelligence (AI) in Healthcare Market reached USD 13,248.65 million in 2022 and is projected to grow significantly, reaching USD 187,704.75 million by 2031, expanding at an impressive CAGR of 41.1% during 2024-2031. The market's rapid growth is driven by the increasing integration of AI technologies across various aspects of healthcare, from clinical diagnosis and imaging to drug discovery, patient monitoring, and hospital…
More Releases for Polycythemia
Polycythemia Vera Market Massive Growth opportunity Ahead
Polycythemia Vera Market Outlook 2024-2034: Rising Diagnosis Rates and Advancements in Targeted Therapies to Drive Growth
Introduction
Polycythemia Vera (PV) is a rare chronic myeloproliferative neoplasm (MPN) characterized by the overproduction of red blood cells, and in some cases, white blood cells and platelets. This leads to increased blood viscosity, higher risk of thrombosis, fatigue, headaches, and splenomegaly. PV is primarily associated with mutations in the JAK2 gene, which has shaped the…
Polycythemia Vera Pipeline: 10+ Therapies in Development by Pharma Giants Poised …
The Polycythemia Vera (PV) treatment landscape is undergoing significant evolution, driven by leading biopharmaceutical companies such as Protagonist Therapeutics, Italfarmaco, Ionis Pharmaceuticals, and Perseus Proteomics. With JAK inhibitors like ruxolitinib already established, the focus has now shifted to next-generation therapeutics targeting disease-modifying mechanisms, cytokine signaling pathways, and novel erythropoiesis regulation. These therapies aim to reduce thrombotic risk, alleviate symptom burden, and delay progression to myelofibrosis.
DelveInsight's "Polycythemia Vera - Pipeline Insight,…
Polycythemia Clinical Trials, Drugs, Key Companies, Polycythemia Treatment Marke …
Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight
Polycythemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Polycythemia treatment therapies, analyzes DelveInsight.
Polycythemia Overview:
Polycythemia, also known as erythrocytosis, is characterized by an increase in red blood cell mass, which is typically identified through laboratory tests showing elevated hemoglobin and hematocrit levels. Polycythemia vera is a specific type of polycythemia, marked by the…
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period.
The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On…
Polycythemia Vera Therapeutics Market Competitive Landscape and Qualitative Anal …
The global polycythemia Vera therapeutics market size was valued at USD 1,500 million in 2021 and is projected to reach around USD 2,200 million in 2030 exhibiting a CAGR of 4.5% in the forecasted period. The rising incidence of polycythemia Vera, growing approval of new products, and boosting collaborations and acquisitions between major players are the main reasons that boost the growth of the global polycythemia Vera therapeutics market. On…
Polycythemia Vera Therapeutics Market to See Incredible Growth During 2021 – 2 …
Polycythemia Vera Therapeutics Market is estimated to be valued at US$ 1,115.9 million in 2021 and is expected to exhibit a CAGR of +4% over the forecast period (2021-2029).
Polycythemia vera is a rare, chronic disorder involving the overproduction of blood cells in the bone marrow (myeloproliferation). The overproduction of red blood cells is most changing, but the production of white blood cells and platelets are also elevated in most cases.…
